Product/Composition:- | Tenofovir Alafenamide (TAF) |
---|---|
Strength:- | 25 mg TAF per tablet |
Form:- | Tablet |
Reference Brands:- | Vemlidy® (EU & US) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Tenofovir Alafenamide (TAF) is a 25 mg oral antiviral used to treat chronic Hepatitis B and HIV-1 infections. It provides higher drug levels inside cells with fewer side effects on kidneys and bones compared to TDF. Marketed as Vemlidy® for Hepatitis B, TAF is approved by FDA and EMA and widely used in the US and EU. It’s a key option for pharma B2B suppliers and healthcare providers managing viral infections.
Tenofovir Alafenamide (TAF) is a next-generation nucleotide reverse transcriptase inhibitor (NRTI) used for the treatment of chronic Hepatitis B virus (HBV) infection and HIV-1. Available as oral tablets, typically in 25 mg strength, TAF delivers higher intracellular concentrations of the active drug with lower plasma exposure, improving safety and reducing kidney and bone side effects compared to Tenofovir Disoproxil Fumarate (TDF). Marketed under the brand name Vemlidy® (for HBV) and as part of combination therapies for HIV, TAF is FDA- and EMA-approved, widely used by pharma B2B suppliers and healthcare providers in the US and EU.